Investigator Sponsored Phase I/II study of AXL1717 in Patients with Brain Tumors
News Apr 25, 2013
Axelar AB has announced that an investigator sponsored Phase I/II study with AXL1717 in patients with malignant astrocytomas, a type of brain tumor, has commenced in the United States.
The study is conducted at the Rush University Medical Center in Chicago in patients with relapsed or progressive malignant astrocytomas (glioblastoma and anaplastic astrocytoma), with AXL1717 - an oral small-molecule insulin-like Growth Factor 1 (IGF-1) receptor inhibitor - as the investigational drug.
Astrocytoma represents about half of all primary tumors of the brain and spinal cord. The most common malignant brain tumors in adults, glioblastomas, make up about two-thirds of all astrocytomas.
This study is also supported by Voices Against Brain Cancer and Gateway for Cancer Research.
More detailed information about the study can be found on www.clinicaltrials.gov (Identifier: NCT01721577).
Dr. Carl Harald Janson, CEO, Axelar AB “We are very pleased to support this investigator sponsored study in astrocytomas with supply of study drug. Preclinical data supports treatment with AXL1717 in patients with astrocytomas and we now look forward to follow this important clinical study, since treatment for astrocytomas remains very challenging and new advances are necessary to improve clinical outcome.”
Understanding the Cellular Systems that Hold Back Cancer from SpreadingNews
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.READ MORE
A Cellular Immune Surveillance Mechanism that Detects Cancer EarlyNews
Fresh insights into how cells detect damage to their DNA – a hallmark of cancer – could help explain how the body keeps disease in check.
Shedding Light on How Tumors Become Resistant to ImmunotherapyNews
Researchers have now found that in skin cutaneous melanoma an epigenetic control protein is key to the development of immunotherapy resistance.READ MORE
Comments | 0 ADD COMMENT
11th International Conference on Cancer Stem Cells
Jun 11 - Jun 13, 2018
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017